Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
04/2003
04/17/2003US20030072752 Two novel genes from psoriatic epidermis: psoriastatin type i and psoriastatin type ii
04/17/2003US20030072751 Idiotypic vaccination against b cell lymphoma
04/17/2003US20030072736 Human tumor necrosis factor receptor TR16
04/17/2003EP0912584A3 New bis-platinum complexes with polyamine ligands as antitumor agents
04/17/2003CA2471968A1 Immunostimulatory nucleic acids and use thereof
04/17/2003CA2463507A1 Methods for the synthesis of substituted purines
04/17/2003CA2463364A1 2-amino-6-(2,4,5-substituted-phenyl)-pyridines for use as nitric oxide synthase inhibitors
04/17/2003CA2463339A1 Controlled release drug delivery composition comprising polycationic polymer and negatively charged pharmacologically active compound
04/17/2003CA2463198A1 Pyrrolidinone derivatives
04/17/2003CA2463049A1 Novel method of assaying immune activity
04/17/2003CA2462950A1 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors
04/17/2003CA2462892A1 Human 3 relaxin
04/17/2003CA2462881A1 Intraorally disintegrating valdecoxib compositions prepared by spray drying process
04/17/2003CA2462862A1 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists
04/17/2003CA2462291A1 Methods and compositions for treating dermal lesions
04/17/2003CA2461435A1 Angiopoietin-2 specific binding agents
04/17/2003CA2461343A1 Mammalian c-type lectins
04/17/2003CA2461145A1 Live attenuated salmonella strains for producing vaccines
04/17/2003CA2461092A1 Pharmaceutical composition for the treatment of disorders of non-human mammals
04/17/2003CA2460625A1 Structural and cytoskeleton-associated proteins
04/17/2003CA2460480A1 Molecules for disease detection and treatment
04/17/2003CA2460476A1 Protein modification and maintenance molecules
04/17/2003CA2458645A1 Intracellular signaling molecules
04/17/2003CA2458464A1 Monoclonal and cdr-grafted antibodies specific for human kdr
04/17/2003CA2458453A1 Acylsulfonamides as inhibitors of steroid sulfatase
04/16/2003EP1302542A1 Novel physiologically active peptide and use thereof
04/16/2003EP1302541A1 Receptor protein specifically recognizing bacterial dna
04/16/2003EP1302539A1 Tumor-specific promoters
04/16/2003EP1302476A1 Reduced fk228 and use thereof
04/16/2003EP1302472A1 Molecules capable of binding to telomere and the like and method with the use of the same
04/16/2003EP1302468A1 Processes and intermediates for manufacturing retroviral protease inhibiting compounds
04/16/2003EP1302460A1 Indolecarboxylic compounds and their use as pharmaceutical compounds
04/16/2003EP1302201A1 Pharmaceutical composition improved in peroral absorbability
04/16/2003EP1301613A2 Modified virus having an altered tropism
04/16/2003EP1301612A2 Method and composition for targeting an adenoviral vector
04/16/2003EP1301611A2 Human rrp sequences and methods of use
04/16/2003EP1301605A2 Nk cells activating receptors and their therapeutic and diagnostic uses
04/16/2003EP1301598A2 Cell cycle proteins and mitosis-associated molecules
04/16/2003EP1301595A2 G-protein coupled receptors
04/16/2003EP1301539A2 Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
04/16/2003EP1301535A2 G-protein coupled receptors
04/16/2003EP1301534A2 Mutated pf-4, its fragments and mutated fusion peptides, their analogues, corresponding dna, cdna and mrna sequences and their use for inhibiting angiogenesis
04/16/2003EP1301531A2 Reagents and methods for identification of binding agents
04/16/2003EP1301528A2 Peptides as ns3-serine protease inhibitors of hepatitis c virus
04/16/2003EP1301524A1 B7-like polynucleotides, polypeptides, and antibodies
04/16/2003EP1301519A2 Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
04/16/2003EP1301518A1 Tricyclic compounds as mrp1-inhibitors
04/16/2003EP1301517A1 Thienopyrrolidinones
04/16/2003EP1301516A1 Modulators of protein tyrosine phosphatases (ptpases)
04/16/2003EP1301514A1 Aryl and heteroaryl diazabicycloalkanes, their preparation and use
04/16/2003EP1301507A2 Mannich base prodrugs of 3 - (pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as modulators of protein kinases
04/16/2003EP1301506A1 Cyclic amino acid derivatives
04/16/2003EP1301500A1 Nitrosated and nitrosylated taxanes, compositions and methods of use
04/16/2003EP1301498A1 Colchinol derivatives as angiogenesis inhibitors
04/16/2003EP1301497A1 Colchinol derivatives as vascular damaging agents
04/16/2003EP1301485A1 Novel heteroaryl derivatives and the use thereof as pharmaceuticals
04/16/2003EP1301480A1 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
04/16/2003EP1301474A2 Tyrosine derivatives as phosphatase inhibitors
04/16/2003EP1301472A2 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
04/16/2003EP1301215A1 Radioactive compositions and methods of use thereof
04/16/2003EP1301212A1 Pharmaceutically active compound
04/16/2003EP1301211A2 Multifunctional nanodevice platform
04/16/2003EP1301209A1 Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
04/16/2003EP1301207A2 Compositions for treating bacterial infections, containing an oxazolidinone compound, sulbactam and and ampicillin
04/16/2003EP1301194A1 Essential oil combination and therapeutic uses thereof
04/16/2003EP1301191A1 Potent immunostimulants from microalgae
04/16/2003EP1301189A2 USE OF 2-METHYLENE-19-NOR-20(S)-1$g(a),25-DIHYDROXYVITAMIN D 3? TO INCREASE BONE STRENGTH
04/16/2003EP1301184A2 Valproic acid and derivatives thereof as histone deacetylase inhibitors
04/16/2003EP1301182A2 Use of matrix metalloprotease inhibitors for the treatment of cancer
04/16/2003EP1240159A4 Improved omeprazole process and compositions thereof
04/16/2003EP1181047B1 Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product
04/16/2003EP1181017B1 Metalloprotease inhibitors
04/16/2003EP1150697B1 High molecular weight extracts of convolvulus arvensis (field bindweed)
04/16/2003EP1094812A4 Angiogenesis inhibitors
04/16/2003EP1056449B1 20-hete antagonists and agonists
04/16/2003EP1043986B1 Mixture and pharmaceutical composition comprising z-4-hydroxytamoxifen and cyclodextrin
04/16/2003EP1009442B1 Improvements in or relating to regulation of t cell activation
04/16/2003EP0991644B1 Benzo(5,6)cycloheptapyridine cyclic ureas and lactams useful as farnesyl protein transferase inhibitors
04/16/2003EP0942896B1 Substituted phenols and thiophenols useful as antioxidant agents
04/16/2003EP0869803B1 Allogeneic paracrine cytokine tumor vaccines
04/16/2003EP0824544B1 Peptidyl compounds which inhibit metalloproteinase and tnf liberation and their therapeutic use
04/16/2003EP0792154B1 Composition of cisplatin in combination with 2,2'-dithio-bis(ethanesulfonate) (dimesna)
04/16/2003EP0789591B1 Methods for identifying individuals suffering from a cellular abnormality
04/16/2003EP0680338B1 Ganglioside-klh conjugate vaccines with qs-21
04/16/2003EP0654083B1 Ptp-d subfamily of protein tyrosine phosphatases
04/16/2003CN1411512A Chimeric immunogenic compositions and nucleir acids encoding them
04/16/2003CN1411458A Saccharin derivatives as orally active elastase inhibitors
04/16/2003CN1411457A Substituted pyrroles
04/16/2003CN1411456A Chemokine receptor binding heterocyclic compounds
04/16/2003CN1411449A N-(1-phenylethyl)-5-phenyl-imidazole-2-amine compounds, their compositions and uses
04/16/2003CN1411447A Polymorphic crystalline forms of celecoxib
04/16/2003CN1411446A Ortho-sulfonamido aryl hydroxamic acids, process for their preparation and their use as matrix metalloproteinase inhibitors
04/16/2003CN1411444A Vitronectin receptor antagonist bicyclic compounds, preparation method and compositions containing same
04/16/2003CN1411442A Farnesyl transferase inhibitors
04/16/2003CN1411441A Farnesyl protein transferase inhibitors
04/16/2003CN1411440A Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof
04/16/2003CN1411376A Novel helicobacter pylori-binding substances and use thereof
04/16/2003CN1410434A Pristimerin series dorivative possessing antioxidation and antitumour activity and its synthesis method
04/16/2003CN1410432A 5-fluro-1-calcium phosphate-uracil
04/16/2003CN1410421A Intermediate for preparing 10-deacetylation baccatin III and 10-deacetylation-14 beta hydroxy baccatin III derivatives
1 ... 1577 1578 1579 1580 1581 1582 1583 1584 1585 1586 1587 1588 1589 1590 1591 1592 1593 1594 1595 1596 1597 ... 2211